Patents Assigned to Glaxo Wellcome Inc.
-
Patent number: 7166287Abstract: The invention relates to post-transfusional non-A non-B hepatitis viral polypeptide, DNA sequences encoding such viral polypeptide, expression vectors containing such DNA sequences, and hosts transformed by such expression vectors. The invention also relates to the use of such polypeptides in diagnostic assays and vaccine formulations.Type: GrantFiled: September 18, 2000Date of Patent: January 23, 2007Assignee: Glaxo Wellcome Inc.Inventors: Peter E. Highfield, Brian C. Rodgers, Richard S. Tedder, John A. J. Barbara
-
Patent number: 7119202Abstract: Disclosed are compounds of the formula wherein R1 is hydrogen or an acyl group having 1 to 16 carbon atoms; R2 is a purine or pyrimidine base or an analogue or derivative thereof; Z is O, S, S?O or SO2; and pharmaceutically acceptable derivatives thereof. Also described are processes for and intermediates of use in their preparation, pharmaceutical compositions containing these compounds, and the use of these compounds in the antiviral treatment of mammals.Type: GrantFiled: June 6, 1995Date of Patent: October 10, 2006Assignee: Glaxo Wellcome Inc.Inventors: Pierrette Belleau, legal representative, Paul Nguyen Ba, Bernard Belleau, deceased
-
Patent number: 7008623Abstract: The invention relates to antibodies which bind to the CD23 (FC?RII) type II molecule particularly altered antibodies including antibodies which bind to the CD23 (FC?RII) type II molecule characterized by an affinity constant equal to or greater than 1×109 Ka Mol?1, the preparation of such antibodies, pharmaceutical compositions which contain such antibodies and their use in therapy particularly in the treatment of autoimmune and inflammatory disorders.Type: GrantFiled: May 7, 1999Date of Patent: March 7, 2006Assignee: Glaxo Wellcome Inc.Inventors: Jean-Yves Marcel Paul Bonnefoy, James Scott Crowe, Jonathan Henry Ellis, Nicholas Timothy Rapson, Jean Shearin
-
Patent number: 6913930Abstract: The present invention relates to an improved analytical method and apparatus therefor, in particular to a method and apparatus for continuous titration in which at least one parameter of at least one compound in a test mixture may be monitored as the composition of the mixture is continuously varied. The method comprises the steps of continuously mixing at least two component fluid streams to form a test mixture stream and passing the test mixture stream through a spectrophotometric detection zone, with the volume to volume ratio of at least two of the component streams forming the test mixture stream continuously and linearly varied with time by alteration of the relative proportions of the component streams forming the test mixture, while the total volume of the test mixture stream remains constant.Type: GrantFiled: August 5, 2003Date of Patent: July 5, 2005Assignee: Glaxo Wellcome Inc.Inventors: Christopher David Bevan, Alan Peter Hill, Derek Peter Reynolds
-
Patent number: 6875449Abstract: A process for the production of crystals with controlled surface smoothness, size, shape and degree of crystallinity, compositions comprising such crystals, and the use of certain crystals, especially lactose, lactose monohydrate, fluticasone propionate, salmeterol xinafoate, salbutamol sulphate or ipratropium bromide in pharmaceutical compositions.Type: GrantFiled: March 24, 1999Date of Patent: April 5, 2005Assignee: Glaxo Wellcome, Inc.Inventors: Christopher Marriott, Gary Peter Martin, Xian-Ming Zeng
-
Publication number: 20040228857Abstract: The invention relates to a CHO cell-line capable of producing antibody, the cell-line having been co-transfected with a vector capable of expressing the light chain of the antibody and a vector capable of expressing the heavy chain of the antibody wherein the vectors contain independently selectable markers; also included is a CHO cell-line capable of producing a human antibody or an altered antibody, the cell-line having been transfected with a vector capable of expressing the light chain of the antibody and the heavy chain of the antibody; process for the production of antibody using a CHO cell-line and antibody having CHO glycosylation.Type: ApplicationFiled: January 28, 2004Publication date: November 18, 2004Applicant: Glaxo Wellcome, Inc.Inventors: Martin J. Page, James S. Crowe
-
Publication number: 20040176342Abstract: A fluticasone lotion having improved vasoconstrictor and anti-inflammatory activity and higher than expected potency. The fluticasone lotion contains 0.05 weight percent fluticasone propionate and an oil-in-water vehicle that includes excipients. The fluticasone lotion is unexpectedly efficacious while exhibiting an improved safety profile.Type: ApplicationFiled: March 15, 2004Publication date: September 9, 2004Applicant: Glaxo Wellcome Inc.Inventors: Gordon J. Dow, Keith Arthur Johnson, Frances Furr Kelly, Robert William Lathrop, Rukmini Rajagopalan
-
Patent number: 6767996Abstract: An altered antibody chain is produced in which the CDR's of the variable domain of the chain are derived from a first mammalian species. The framework-encoding regions of DNA encoding the variable domain of the first species are mutated so that the mutated framework-encoding regions encode a framework derived from a second different mammalian species. The or each constant domain of the antibody chain, if present, are also derived from the second mammalian species.Type: GrantFiled: May 17, 1993Date of Patent: July 27, 2004Assignee: Glaxo Wellcome Inc.Inventors: Scott David Gorman, Michael Ronald Clark, Stephen Paul Cobbold, Herman Waldmann
-
Patent number: 6706244Abstract: Devices and methods are provided to facilitate the evaluation of the quality of a combinatorial library of compounds. One exemplary device comprises a holding plate having an array of apertures. A plurality of vials are removably held within the apertures. Each of the vials has an open top end. A seal member is disposed over the top ends of the vials, and a top plate is removably coupled to the holding plate to force the seal member against the top ends of the vials.Type: GrantFiled: December 30, 1998Date of Patent: March 16, 2004Assignee: Glaxo Wellcome Inc.Inventors: Frank R. Holden, William L. Fitch, Kenneth C. Lewis
-
Publication number: 20040023405Abstract: The present invention relates to an improved analytical method and apparatus therefor, in particular to a method and apparatus for continuous titration in which at least one parameter of at least one compound in a text mixture may be monitored as the composition of the mixture is continuously varied.Type: ApplicationFiled: August 5, 2003Publication date: February 5, 2004Applicant: Glaxo Wellcome Inc.Inventors: Christopher David Bevan, Alan Peter Hill, Derek Peter Reynolds
-
Publication number: 20030166299Abstract: A system for processing a plurality of solid supports comprises a tubular member having a proximal end, a distal end, and a lumen terminating at the distal end. A stop is positioned within the lumen at a location spaced about the distal end and is sized to permit fluids to pass through the lumen while preventing the passage of solid supports. A fluid transfer device is configured to transfer fluids through the lumen such that when a fluid containing one or more solid supports is aspirated into the lumen, a solid support may be drawn into the lumen to lodge against the stop.Type: ApplicationFiled: September 12, 2002Publication date: September 4, 2003Applicant: Glaxo-Wellcome, Inc., A North Carolina corporationInventors: Svetlana Velkovska, Kerwin Ng, Haim Kedar
-
Publication number: 20030138411Abstract: The invention provides a cloned polynucleotide having the function of a transcriptional regulatory sequence (trs) and comprising: (a) a polynucleotide fragment having at least 70% identity to the polynucleotide of SEQ ID NO.:2; (b) a polynucleotide which is complementary to the polynucleotide of (a); or (c) a polynucleotide comprising at least 15 sequential bases of the polynucleotide of (a) or (b).Type: ApplicationFiled: February 1, 2002Publication date: July 24, 2003Applicant: Glaxo Wellcome Inc.Inventor: David Robert Greaves
-
Publication number: 20030118514Abstract: Elongated drug, especially salbutamol sulphate, and/or carrier particles, especially lactose, pharmaceutical compositions comprising the same, and use of the elongated particles in the manufacture of a medicament for the treatment of respiratory disease.Type: ApplicationFiled: August 26, 2002Publication date: June 26, 2003Applicant: Glaxo Wellcome Inc.Inventors: El Hassane Larhrib, Christopher Marriott, Gary Peter Martin, John Nigel Pritchard, Xian Ming Zeng
-
Publication number: 20030096788Abstract: A method of treating a patient suffering from or susceptible to ischemic heart disease, peripheral vascular disease or stroke or which subject is suffering pain, a CNS disorder or sleep apnea which comprises administering a therapeutically effective amount of an adenosine derivative which is an agonist at the adenosine A1 receptor and which exhibits little or no agonist activity of the A3 receptor.Type: ApplicationFiled: August 13, 2002Publication date: May 22, 2003Applicant: Glaxo Wellcome Inc.Inventors: David Edmund Bays, Richard Peter Charles Cousins, Hazel Joan Dyke, Colin David Eldred, Brian David Judkins, Martin Pass, Andrew Michael Kenneth Pennell
-
Publication number: 20030035799Abstract: The invention relates to a CHO cell-line capable of producing antibody, the cell-line having been co-transfected with a vector capable of expressing the light chain of the antibody and a vector capable of expressing the heavy chain of the antibody wherein the vectors contain independently selectable markers; also included is a CHO cell-line capable of producing a human antibody or an altered antibody, the cell-line having been transfected with a vector capable of expressing the light chain of the antibody and the heavy chain of the antibody; process for the production of antibody using a CHO cell-line and antibody having CHO glycosylation.Type: ApplicationFiled: May 16, 2002Publication date: February 20, 2003Applicant: Glaxo Wellcome Inc.Inventors: Martin J. Page, James S. Crowe, Nicholas T. Rapson, Michael J. Keen
-
Publication number: 20030022904Abstract: A compound of formula (I) wherein R1 is phenyl substituted by one or more halogen atoms; R2 is —NH2; R3 is —NH2 or hydrogen; R4 is —CXNRaRb, —CXNH—(CH2)y—NRaRb; wherein X is ═O or ═S; y is an integer zero, 1 or 2; Ra and Rb, which may be the same or different, are selected from hydrogen and C1-4 alkyl or together with the nitrogen atom to which they are attached form a saturated 5- or 6-membered heterocycle containing one or two nitrogen heteroatoms, which heterocycle can be further substituted with one or more C1-4 alkyl groups; and pharmaceutically acceptable derivatives thereof.Type: ApplicationFiled: August 12, 2002Publication date: January 30, 2003Applicant: Glaxo Wellcome Inc.Inventors: Brian Cox, Mark Patrick Healy, Deborah Wild
-
Publication number: 20020182208Abstract: The invention relates to a CHO cell-line capable of producing antibody, the cell-line having been co-transfected with a vector capable of expressing the light chain of the antibody and a vector capable of expressing the heavy chain of the antibody wherein the vectors contain independently selectable markers; also included is a CHO cell-line capable of producing a human antibody or an altered antibody, the cell-line having been transfected with a vector capable of expressing the light chain of the antibody and the heavy chain of the antibody; process for the production of antibody using a CHO cell-line and antibody having CHO glycosylation.Type: ApplicationFiled: May 16, 2002Publication date: December 5, 2002Applicant: Glaxo Wellcome, Inc.Inventors: Martin J. Page, James S. Crowe
-
Publication number: 20020169172Abstract: Compounds of formula (I) 1Type: ApplicationFiled: May 16, 2001Publication date: November 14, 2002Applicant: GLAXO WELLCOME INC.Inventors: Brian Cox, Dean David Edney, Michael Simon Loft, Malcolm Stuart Nobbs, Gita Punjabhai Shah
-
Patent number: RE37918Abstract: This invention relates to a methodology for assessing the sensitivity of an HIV-1 sample to zidovudine and to diagnostic assays for use in such assessment.Type: GrantFiled: April 23, 1997Date of Patent: December 3, 2002Assignee: Glaxo Wellcome, Inc.Inventors: Brendan A. Larder, Sharon D. Kemp nee Symons
-
Patent number: RE43898Abstract: An altered antibody chain is produced in which the CDR's of the variable domain of the chain are derived from a first mammalian species. The framework-encoding regions of DNA encoding the variable domain of the first species are mutated so that the mutated framework-encoding regions encode a framework derived from a second different mammalian species. The or each constant domain of the antibody chain, if present, are also derived from the second mammalian species.Type: GrantFiled: September 16, 1991Date of Patent: January 1, 2013Assignee: Glaxo Wellcome Inc. ResearchInventors: Scott David Gorman, Michael Ronald Clark, Stephen Paul Cobbold, Herman Waldmann